Glenmark Pharmaceuticals is a research-driven global pharmaceutical company engaged in developing, manufacturing, and marketing branded formulations, generic medicines, specialty products, and active pharmaceutical ingredients. Founded in 1977 by Gracias Saldanha, the company has established operations across more than 80 countries with a diversified presence in India, Europe, North America, Latin America, and emerging markets. Glenmark has developed expertise in dermatology, respiratory diseases, oncology, and chronic therapies while investing significantly in novel drug discovery and biologics research. The company operates multiple state-of-the-art manufacturing facilities that meet stringent international quality and regulatory standards, supporting its expanding global footprint. Through continuous investment in innovation, strategic collaborations, and specialty medicine development, Glenmark aims to address unmet medical needs while delivering affordable healthcare solutions. Its balanced business model, combining branded products, generics, and innovation, positions the company among India’s leading research-oriented pharmaceutical organizations.
NSE: GLENMARK | BSE: 532296
Mumbai, Maharashtra, India
